Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;26(9):1177-1178.
doi: 10.18553/jmcp.2020.26.9.1177a.

The Authors Respond

Mindy L Simpson  1 , Vidhi Desai  2 , Géraldine S Maro  3 , Songkai Yan  2
Affiliations
Comment

The Authors Respond

Mindy L Simpson et al. J Manag Care Spec Pharm. 2020 Sep.

Abstract

No funding was received for the writing of this letter. Simpson reports consulting honoraria for participation in advisory boards for Bayer, CSL Behring, HEMA Biologics, Novo Nordisk, Octapharma and Takeda, and speakers bureau for Bayer and Novo Nordisk; Yan and Desai are employees of CSL Behring; Maro is an employee of Adivo Associates.

PubMed Disclaimer

Conflict of interest statement

No funding was received for the writing of this letter. Simpson reports consulting honoraria for participation in advisory boards for Bayer, CSL Behring, HEMA Biologics, Novo Nordisk, Octapharma and Takeda, and speakers bureau for Bayer and Novo Nordisk; Yan and Desai are employees of CSL Behring; Maro is an employee of Adivo Associates.

Comment on

References

    1. Klamroth R, Simpson M, Depka-Prondzinski M, et al. . Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A. Haemophilia. 2016;22(5):730-38. - PubMed
    1. Graf L. Extended half-life factor VIII and factor IX preparations. Transfus Med Hemother. 2018;45(2):86-91. - PMC - PubMed
    1. Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med. 2017;6(4):39. - PMC - PubMed
    1. Tiede A, Cid AR, Goldmann G, et al. . Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A. Thromb Haemost. 2020;120(2):277-88. - PubMed
    1. Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica. 2013;98(9):1481-86. - PMC - PubMed

LinkOut - more resources